Firas Rahhal, MD
Ophthalmology · Los Angeles, CANPI 1881658615
Payments from drug & device makers
Across 394 payments — averaging $3143.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche TCRC, Inc.$543K
- Kyowa Kirin, Inc.$274K
- Beaver-visitec International, Inc.$112K
- Alcon$88K
- Alcon Research LLC$82K
- Regeneron$66K
- plus $73K from 24 others
What the payments were for
- Consulting fees$231,23288%
- Speaking & faculty fees$15,8006%
- Travel & lodging$6,3862%
- Food & beverage$10,1884%
- Education$930%
- Gifts$1160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roche TCRC, Inc. | 48 | $542,752 |
| Kyowa Kirin, Inc. | 87 | $274,432 |
| Beaver-visitec International, Inc. | 7 | $112,358 |
| Alcon | 65 | $88,289 |
| Alcon Research LLC | 13 | $81,554 |
| Regeneron | 3 | $65,955 |
| Boehringer Ingelheim | 13 | $40,322 |
| Coherus Oncology, Inc. | 10 | $15,723 |
| AbbVie(2 entities) | 34 | $3,714 |
| Astellas Pharma US Inc | 5 | $3,198 |
| Carl Zeiss Meditec, Inc. | 3 | $2,836 |
| Daiichi Sankyo Inc. | 7 | $1,394 |
| Boehringer Ingelheim International GmbH | 17 | $1,379 |
| Apellis Pharmaceuticals, Inc. | 17 | $1,011 |
| Alimera Sciences, Inc. | 4 | $775 |
| Genentech USA, Inc. | 20 | $518 |
| Regeneron Healthcare Solutions, Inc. | 13 | $514 |
| Sandoz | 3 | $281 |
| Eyepoint US, Inc. | 3 | $272 |
| Amgen | 3 | $266 |
| Ocular Therapeutix, Inc. | 4 | $216 |
| Mallinckrodt Hospital Products Inc. | 5 | $198 |
| Bausch & Lomb Americas Inc. | 1 | $150 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $125 |
| Novartis | 1 | $102 |
| Genentech, Inc. | 1 | $77 |
| Biogen | 3 | $66 |
| Baxter Healthcare | 1 | $58 |
| Oculus Surgical Inc. | 1 | $23 |
| GSK | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Constellation$51,945
- Unity$21,531
- Cimerli$15,596
- ARGOS$7,000
- Systane$7,000
- LenSx$7,000
- Hydrus Microstent$7,000
- ILUX$7,000
- Izervay$3,054
- Non-Covered Product$1,848
- NGENUITY$1,546
- FINESSE SHARKSKIN$956
- Iluvien$750
- Syfovre$412
- Alcon Greishaber Finesse$345
- EYLEA$133
- STELLARIS PC$125
- DEXYCU$125
- YUTIQ$123
- BEOVU$102
How this compares
$1,238,576 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 31 | $21,022 |
| ProlensaBromfenac Sodium | 39 | $20,372 |
| LumiganBimatoprost | 51 | $19,851 |
| Brimonidine Tartrate | 269 | $14,516 |
| CombiganBrimonidine Tartrate/Timolol | 47 | $13,289 |
| XiidraLifitegrast | 12 | $11,317 |
| Prednisolone Acetate | 242 | $11,185 |
| Alphagan PBrimonidine Tartrate | 22 | $7,094 |
| MoxifloxacinMoxifloxacin Hcl | 319 | $6,317 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 33 | $5,646 |
| Bromfenac Sodium | 28 | $5,096 |
| RhopressaNetarsudil Mesylate | 15 | $4,686 |
| VyzultaLatanoprostene Bunod | 18 | $4,294 |
| Cyclosporine | 15 | $3,905 |
| Travoprost | 28 | $3,776 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $3,714 | $61,256151 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $125 | $20,37239 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $150 | $15,61030 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Los Angeles
- Steven JacobsonLos Angeles$4.7M
- David BoyerLos Angeles$4M
- Nicole FramLos Angeles$1.2M
- Andrew MoshfeghiLos Angeles$1M
- Pradeep PrasadLos Angeles$901K
- Barry SeibelLos Angeles$835K
- David LiaoLos Angeles$722K
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.